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ABSTRACT 
Objectives: The Illness Invalidation Inventory (3*I) assesses patients’ perception of 
responses of others that are perceived as denying, lecturing, not supporting, and not 
acknowledging the condition of the patient. It includes two factors: ‘discounting’ and ‘lack of 
understanding’. In order to use the 3*I to compare and to pool scores across groups and 
countries, the questionnaire must have measurement invariance; that is, it should measure 
identical concepts with the same factor structure across groups. The aim of this study was to 
examine measurement invariance of the 3*I across rheumatic diseases, gender, and languages. 
Methods: Participants with a rheumatic disease from various countries completed an on-line 
study, which included the 3*I and which was presented in Dutch, English, French, German, 
Portuguese, and Spanish; 6,057 people with rheumatic diseases participated. Single and 
multiple group confirmatory factor analyses were used to test the factorial structure and 
measurement invariance of the 3*I with Mplus. 
Results: The model with strong measurement invariance, i.e. equal factor loadings and 
thresholds (distribution cut points) across gender and rheumatic disease (fibromyalgia versus 
other rheumatic diseases) had the best fit estimates for the Dutch version, and had good fit 
estimates across the six language versions. 
Conclusions: The 3*I showed measurement invariance across gender, rheumatic disease, and 
language. Therefore, it is appropriate to compare and to pool scores of the 3*I across groups. 
Future research may use the questionnaire to examine antecedents and consequences of 
invalidation as well as the effect of treatments targeting invalidation. 
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INTRODUCTION 
Invalidation, defined as the perception of cognitive, affective, and behavioural responses of 
others that are judged to be denying, lecturing, not supporting, and not acknowledging the 
condition of the patient,[1] is problematic for some patients with rheumatic diseases. 
Symptoms of rheumatic diseases such as pain, fatigue, and stiffness are mostly invisible and 
because of this, people in the social environment of the patient might forget or misjudge the 
burden and consequences of the illness.[2] When there is no clinical or laboratory evidence to 
account for the symptoms of the rheumatic illness, such as in fibromyalgia,[3] this can 
provoke even more serious disbelief and distrust towards the patients.[4] Indeed, patients with 
fibromyalgia reported that invalidation is a major issue in their lives, adding a burden to the 
symptoms.[1, 5] Moreover, invalidation could increase the risk of becoming more physically 
impaired and depressed,[6] thus highlighting the need for attending to invalidation in research 
and clinical settings.[7] 
 The Illness Invalidation Inventory (3*I) is a self-report questionnaire that assesses 
patients’ invalidation. An initial evaluation suggested internal consistency and concurrent 
validity of the inventory.[6] To be able to use the 3*I in epidemiological studies, to make 
comparisons of invalidation across patient groups and countries, and to examine its 
antecedents and consequences, the questionnaire must measure identical constructs with the 
same structure across groups. This means that the factor structure, factor loadings, and 
thresholds should be comparable across groups,[9] which is called measurement invariance. 
Thresholds are the points on the unobserved normal distribution where, on average, 
respondents vary between two different response options.[8] When measurement invariance is 
absent, groups or subjects respond differently to items, and factor means cannot validly be 
compared across groups. As yet, it is unclear whether the 3*I shows measurement invariance 
across rheumatic diseases, gender, and languages.  
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 The 3*I assesses invalidation by the spouse, family, medical professionals, work 
environment, and social services using eight items for each of these five social sources 
(Figure 1). The structure for each social source comprises two factors; discounting (5 items) 
and lack of understanding (3 items). Discounting represents active negative social responses 
including disbelieving, admonishing, dismissing inability to work, not acknowledging 
symptom fluctuations, and offering unusable advice. Lack of understanding reflects a lack of 
positive social responses such as not recognising, comprehending, and emotionally supporting 
the patient or illness. To date, the Dutch version of the 3*I has been validated in patients with 
rheumatoid arthritis and fibromyalgia,[6] but measurement invariance across rheumatic 
diseases, gender, and language versions of the 3*I has not been tested. Furthermore, 
qualitative studies suggest that invalidating experiences of patients with rheumatic diseases 
are common in many countries.[4, 5, 10, 11] However, the study of invalidation across 
countries is only legitimately possible after the equivalence of the language versions (other 
than Dutch) of the 3*I has been established.  
 The first aim of the current study was to test the factor structure in a large sample of 
Dutch patients with several rheumatic diseases and to examine measurement invariance 
between patients with fibromyalgia and patients with other rheumatic diseases and between 
men and women. The second aim was to examine measurement invariance between different 
language versions (Dutch, English, French, German, Portuguese, and Spanish).  
 
 
METHODS 
Participants 
Participants were 6,057 people with rheumatic diseases from different countries. Inclusion 
criteria were (1) the self-report of a rheumatic disease, (2) the report that the disease was 
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diagnosed by a medical specialist, general practitioner, or nurse, (3) being 18 years or older, 
and (4) speaking Dutch, English, French, German, Portuguese, or Spanish. Table 1 shows the 
characteristics of the participants, who had a mean age of 45.7 years and were mostly female 
(88%). With the exception of the German respondents, patients with fibromyalgia constituted 
the largest percentage of respondents (40-76% across different languages). The German 
version of the questionnaire was completed by patients with a wide range of conditions, 
particularly systemic lupus erythematosus (29%) and ankylosing spondylitis (25%). Overall, 
patients with osteoarthritis (8-28%), rheumatoid arthritis (6-20%), and Sjögren’s syndrome 
(4-21%) were well represented in the study.   
 
Procedure 
The study was conducted according to the principles of the Declaration of Helsinki [12] and 
was tested and approved by the Medical Ethical Committee of the University Medical Center 
Utrecht.  
 The software program “Netquestionnaires” [13] was used to develop online 
international questionnaires. An online version was first developed for the Dutch version, 
which was pretested among a small sample of Dutch patients. After translation, the other 
language versions were developed uniformly and pre-tested by a small expert group. 
Participants were invited via a recruitment notice on websites of patient associations 
for rheumatic diseases. Patient associations in Dutch, English, French, German, Portuguese, 
and Spanish language countries were asked to put the recruitment notice on their website. The 
text of this notice was similar across countries and patient associations. It is unknown whether 
(some) patient organizations took additional actions to bring the call to the notice of patients. 
On the website, participants could choose one of the six language versions of the study. The 
recruitment notice included information about the aim and content of the study, inclusion 
 6 
criteria, duration of participation (about 20 minutes), and a hyperlink to the online 
questionnaire. Participants could decide to participate after being informed about the study, 
and were able to stop at any point if they desired. Of 8,293 participants who began filling out 
the questionnaire, 6,057 (77%) completed it and provided the data analyzed here. About 80% 
of drop outs were participants who stopped filling out the questionnaire while responding to 
the first demographic questions. 
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Table 1 Demographic characteristics of patients with rheumatic diseases for the six language versions 
Characteristics Dutch English French German Portuguese Spanish 
Sample size 1855 774 735 513 727 1453 
Gender; female, n (%) 1608 (86%) 717 (93%) 688 (94%) 403 (79%) 628 (86%) 1308 (90%) 
Age (yrs), mean (SD) 46.9 (12.7) 47.2 (11.3) 46.5 (11.4) 46.5 (12.3) 42.9 (12.6) 44.1 (11.4) 
Rheumatic disease, n (%)     
  Ankylosing spondylitis 236 (13%) 6 (1%) 52 (7%) 129 (25%) 61 (8%) 104 (7%) 
  Bursitis / Tendinitis 89 (5%) 93 (12%) 45 (6%) 22 (4%) 85 (12%) 148 (10%) 
  Fibromyalgia 737 (40%) 591 (76%) 482 (65%) 65 (13%) 303 (42%) 778 (54%) 
  Gout or Pseudogout 31 (2%) 7 (1%) 1 (0.1%) 6 (1%) 9 (1%) 2 (0.3%) 
  Juvenile arthritis 6 (0.3%) 6 (1%) 1 (0.1%) 8 (2%) 15 (2%) 49 (3%) 
  Osteoarthritis 518 (28%) 155 (20%) 176 (24%) 40 (8%) 105 (14%) 212 (15%) 
  Polymyalgia rheumatica 17 (1%) 4 (1%) 15 (2%) 4 (1%) 5 (1%) 37 (3%) 
  Psoriatic arthritis 102 (6%) 24 (3%) 10 (1%) 26 (5%) 31 (4%) 34 (2%) 
  Raynaud’s phenomenon 76 (4%) 70 (9%) 78 (11%) 79 (15%) 24 (3%) 71 (5%) 
  Rheumatoid arthritis 323 (17%) 137 (18%) 46 (6%) 68 (13%) 148 (20%) 271 (19%) 
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  Sarcoidosis  3 (0.2%) 2 (0.3%) 2 (0.3%) 9 (2%) 2 (0.3%) 1 (0.1%) 
  Scleroderma 26 (1%) 10 (1%) 4 (1%) 45 (9%) 9 (1%) 27 (2%) 
  Sjögren’s syndrome 122 (7%) 34 (4%) 91 (12%) 106 (21%) 25 (3%) 137 (9%) 
  Systemic lupus    
  erythematosus 
197 (6%) 18 (2%) 125 (17%) 146 (29%) 122 (17%) 233 (16%) 
  Other rheumatic disease 244 (13%) 70 (9%) 65 (9%) 72 (14%) 87 (12%) 198 (14%) 
Note. Percentages of rheumatic diseases can exceed 100% because participants may have more than one rheumatic disease 
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Instruments 
The on-line study included items about demographic characteristics and the Illness 
Invalidation Inventory.  
The Illness Invalidation Inventory (3*I) [6] measures invalidation by each of 5 sources 
(spouse, family, medical professionals, work environment, and social services). It consists of 
2 factors: discounting (5 items) and lack of understanding (3 items; see Figure 1). Participants 
indicate on a 5-point scale (1=never, 2=seldom, 3=sometimes, 4=often, 5=very often) how 
frequently during the past year people within each category responded to them in the 
described way. A source category that does not apply can be skipped. An initial validation 
study in Dutch patients demonstrated good reliability and validity of the 3*I.[6] 
 Translation of the 3*I was done by the forward-and-backward translation method. 
First, the Dutch version of the 3*I was translated by a native English and Dutch speaker to 
English. When consensus was reached about the English version, another native English and 
Dutch speaker translated the English version back to Dutch. After consensus was reached 
between translators and researchers, the final English version of the questionnaire was 
determined. The English version of the questionnaire was used for the translation to other 
languages. For each translation, the forward-and-backward translation method was used by 
two native English speakers and two native speakers of the other language. 
 
Measurement invariance  
The first step to determine measurement invariance is to specify the model (adequate 
structure) of the instrument.[14] With confirmatory factor analyses (CFA) the factor structure 
of the model is tested for each group. The second step is to check whether the best fitting 
factor model is adequate and equal across groups. This can be tested first, by comparing the 
numerical values of the factor loadings across groups, which should be similar (weak 
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invariance); and, second, by comparing whether the thresholds are similar across groups 
(scalar invariance).[15] For straightforward interpretation of latent variable means and 
patterns of correlations across groups, both the factor loadings and thresholds should be 
similar across groups (strong invariance).[16]  
 When weak invariance is not supported, this could mean that one or more of the 
common factors have different meanings across the population groups [17] or that a subset of 
the factor loading estimates for a group is biased due to extreme response style. When strong 
invariance is not supported, differential additive response bias or differential acquiescence 
response styles might be the problem.[18] 
 
Statistical analysis 
Single and multiple group CFAs were used to test the factorial structure and measurement 
invariance by means of Mplus 6.11.[19]  
 First, the Dutch data were used to check whether the model displayed in Figure 1 with 
two factors fits to the data better than a one-factor model. Furthermore, we investigated 
whether the model fits better to the data with continuous or with ordered categorical 
indicators. Because a model including all sources of the 3*I with categorical indicators was 
too complex for Mplus to compute, the model was run for each source separately (spouse, 
family, medical professionals, work environment, and social services). In the Results section, 
the statistics for the source ‘family’ are presented because this source applies to almost all 
participants. Results for the other four sources are presented in a Supplementary file.   
Due to non-normally distributed item scores, a robust weighted least squares estimator 
(WLSMV) was used. Full information maximum likelihood estimation was used to include 
participants with a score on at least one item of a subscale.[20] To assess model fit, we used 
the comparative fit index (CFI), Tucker-Lewis index (TLI), and root mean square error of 
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approximation (RMSEA). Cut-off values for fit were considered adequate if CFI and TLI 
values are > 0.90 and RMSEA < 0.08. The Bayesian information criterion (BIC) was used to 
compare competing models. A lower BIC indicates a better trade-off between model fit and 
model complexity. Because the BIC value is not estimated by the WLSMV estimator, all 
models were repeated using a maximum likelihood estimator (MLR), again using a correction 
for non-normality. 
 In a second step of analyses, measurement invariance across rheumatic diseases was 
tested in the Dutch data for patients with only fibromyalgia versus patients with one other 
rheumatic disease (n = 890). The other 548 patients who reported having two or more co-
morbid rheumatic diseases were excluded from this analysis. Third, measurement invariance 
across gender was tested in the Dutch data. Fourth, measurement invariance was tested across 
languages in the international data using a similar procedure.  
 In each test of measurement invariance, three models were analyzed; Model 1 includes 
constrained factor loadings, thresholds free (weak invariance), Model 2 includes constrained 
thresholds, factor loadings free (scalar invariance), and Model 3 includes both constrained 
factor loadings and thresholds (strong invariance) [21].  
 In a last step of analysis, standardized factor loadings, threshold values, and internal 
consistency (Cronbach’s alpha) were examined.  
 
RESULTS 
Factor structure of the Illness Invalidation Inventory 
For several items of the 3*I, the score distribution across the response categories were 
skewed. Therefore, one- and two-factor models with continuous factor indicators were 
compared to a one- and two-factor model where the items were defined as being categorical. 
Table 2 shows outcomes of the four CFA for the 3*I source ‘family’ factor structure in the 
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Dutch data. The two-factor model with categorical items provided the better trade-off 
between model fit and model complexity according to the BIC criterion and it had adequate 
fit estimates. Analyses for the four other social sources were repeated and the two-factor 
model with categorical items also showed the best fit for each source (Supplementary file, 
Table S1). This model has been used in subsequent analyses. 
 
Table 2 Fit statistics of confirmatory factor analyses of the 3*I source ‘family’ for the one 
and two-factor solution including continuous or categorical factor indicators in the Dutch 
sample (n = 1855) 
Model: ² df CFI TLI RMSEA BIC 
One-factor 
continuous 
1040.94 20 0.90 0.86 0.17 37236 
One-factor 
categorical 
16064.02 390363  0.97 0.95 0.20 34158 
Two-factor 
continuous 
    279.29 19 0.97 0.96 0.09 36482 
Two-factor 
categorical 
15931.29 390397  0.99 0.99 0.10 33615 
Note. CFI = comparative fit index, TLI = Tucker-Lewis index, RMSEA = root mean square error of 
approximation, BIC = Bayesian information criterion. The df-value differs between the continuous 
and categorical models due to a high number of parameter estimators in the categorical model, since 
there are k (response categories)-1 thresholds 
 
Measurement invariance 3*I across rheumatic diseases  
Table 3 shows outcomes of the CFA for the source ‘family’ of the 3*I for fibromyalgia versus 
other rheumatic diseases in the Dutch data. The three models were tested for each source of 
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the 3*I. Although Model 1a had the lowest ²-value and RMSEA, and the largest CFI and 
TLI, the fit indices were also acceptable for Model 3a. The BIC value was lowest for Model 
3a, which shows that Model 3a with both the factor loadings and thresholds constrained is 
simpler than Model 1a; it is the preferred model because it has a better trade-off between 
model fit and model complexity. The BIC value was also lowest for Model 3a among the 
other sources (Supplementary file, Table S2). Therefore, Model 3a was chosen as the best 
model indicating measurement invariance across rheumatic diseases.  
 
Table 3 Test of measurement invariance of source ‘family’ of the 3*I of rheumatic disease 
(fibromyalgia versus other rheumatic disease) and gender in the Dutch sample, and of 
language in the international sample  
Source 3*I ² df CFI TLI RMSEA BIC 
Rheumatic disease 
(n = 1314) 
      
Model 1a:  
thresholds free 
16027.22 780967 0.99 0.99 0.08 25352 
Model 2a: factor 
loadings free 
16928.29 780997 0.98 0.98 0.11 25319 
Model 3a:  
factor loadings + 
thresholds fixed 
16430.65 781001 0.98 0.99 0.10 25281 
Gender (n = 1855)       
Model 1b:  
thresholds free 
18223.51 780943 0.99 0.99 0.09 35368 
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Model 2b: factor 
loadings free 
18325.51 780966 1.00 1.00 0.06 35236 
Model 3b:  
factor loadings + 
thresholds fixed 
18427.46 780975 1.00 1.00 0.05 35185 
Language (n = 
6027) 
      
Model 1c:  
thresholds free 
85824.25 2342233 0.99 0.99 0.08 139064 
Model 2c: factor 
loadings free 
88422.58 2342289 0.98 0.99 0.10 140846 
Model 3c:  
factor loadings + 
thresholds fixed 
89713.99 2342336 0.98 0.99 0.09 140984 
Note. CFI = comparative fit index, TLI = Tucker-Lewis index, RMSEA = root mean square error of 
approximation, BIC = Bayesian information criterion. 
 
Measurement invariance 3*I across gender 
Measurement invariance was also tested across gender in the Dutch data. Table 3 shows the 
fit-estimates for the source ‘family’. Model 3b (strong invariance) best fitted the data: it had 
adequate CFI, TLI and RMSEA values and the lowest BIC value. Model 3b showed also the 
lowest BIC value among the other sources (Supplementary file, Table S3). This supports 
measurement invariance across gender.  
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Measurement invariance 3*I across languages 
In the separate English, French, German, Portuguese, and Spanish data sets, CFA was 
conducted to examine the two-factor structure of the 3*I for each language version of the 3*I 
as compared to the Dutch factor structure. The two-factor model showed adequate fit 
estimates for each language version of the 3*I (results are not shown). Because this result 
confirmed the equivalence of factor structures of the 3*I across languages, it was feasible to 
study measurement invariance of the 3*I across the languages.  
A multiple group model including all data sets was created to compare Models 1c, 2c 
and 3c across languages. Fit estimates are shown in Table 3 for the source ‘family’ of the 3*I. 
All Models (1c, 2c, and 3c) showed adequate CFI and TLI estimates. The fit-estimates 
showed the best fit for model 1c (weak invariance): in general it had the lowest ²-value, 
RMSEA, and BIC and the largest CFI and TLI. This model 1c (constrained factor loading, 
thresholds free) indicates that the factor loadings are invariant across languages, but that 
threshold values are non-invariant across languages.  
To illustrate this finding, consider the standard factor loadings obtained with Model 1c 
(factor loadings free, Table 4). The factor loadings differ barely between language versions of 
the 3*I. Thus, constraining these factor loadings to be equal resulted in a simpler model (i.e., 
less parameters have to be estimated) and it yields a better fit (Table 3).  
Table 5 shows the thresholds of items 1 and 2 for the source ‘family’ of the 3*I in 
each language version. The results indicate differences between languages, for example item 
2 threshold 2 shows -0.25 for the French version and 0.40 for the German version. If we 
constrain the thresholds to be equal (Model 3c), the BIC indicates that, although model 3C is 
simpler, the fit has worsened. 
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Table 4 Standardized factor-loadings for 3*I for each language version 
Items per Factor loadings 
factor Dutch English French German Portuguese Spanish 
Discounting by family      
   Item 1 0.74 0.77 0.74 0.84 0.76 0.76 
   Item 2 0.83 0.84 0.87 0.91 0.84 0.91 
   Item 4 0.48 0.50 0.38 0.71 0.56 0.46 
   Item 6 0.89 0.93 0.92 0.93 0.92 0.95 
   Item 7 0.86 0.93 0.91 0.92 0.91 0.93 
Lack of understanding by family     
   Item 3 0.85 0.87 0.90 0.91 0.89 0.93 
   Item 5 0.80 0.86 0.88 0.89 0.87 0.91 
   Item 8 0.77 0.80 0.86 0.84 0.82 0.85 
Note. Cross-loadings are set to zero in confirmatory factor analyses.  
 
Table 5 Thresholds item 1 and 2 of the source ‘family’ of the 3*I of each language version 
Items per  
factor Dutch English French German Portuguese Spanish 
Family discounting      
   Item 1 threshold 1 -0.78 -1.07 -0.79 -0.50 -0.32 -0.68 
   Item 1 threshold 2 -0.19 -0.57 -0.36 0.04 0.13 -0.26 
   Item 1 threshold 3 0.73 0.35 0.35 0.82 0.95 0.33 
   Item 1 threshold 4 1.66 1.13 1.13 1.63 1.68 0.85 
   Item 2 threshold 1 -0.47 -0.68 -0.70 -0.18 -0.50 -0.51 
   Item 2 threshold 2 0.20 -0.15 -0.25 0.40 -0.01 -0.17 
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   Item 2 threshold 3 0.94 0.55 0.30 1.01 0.64 0.31 
   Item 2 threshold 4 1.73 1.29 1.04 1.72 1.37 0.78 
Note. A 5-point response scale contains four thresholds, because thresholds divide the 
distribution into distinct categories equal to the number of categories minus one. 
 
The fit of Model 3c could be improved through partial measurement invariance (setting some 
thresholds “free”, but constraining others). To identify non-invariant thresholds, both the 
Modification Index (MI) for a parameter, which gives the expected drop in the model’s Chi-
square value if the parameter is freely estimated, and the value of thresholds across languages 
can be studied. Ideally, one or two items, or one or two languages would be identified 
explaining non-invariant thresholds. In that case, a solution would be to delete these items, or 
to deal differently with computation of factors in this language. In our study, the German data 
seem most different. However, close inspection of the MI and the (5 times 32) threshold 
values across languages did not show significant MI’s or specific threshold patterns. 
Therefore, determining the degree of partial measurement invariance was not attainable. 
Because the model assuming strong measurement invariance still has a good fit to the data 
(i.e., most model fit indices are well above the cut-off values) and differences in threshold 
values probably cancel each other out between the different languages[8, 22], we concluded 
that Model 3c applies for all social sources (Supplementary file, Table S4). The Cronbach’s 
alpha per language indicated that the internal consistency of the two 3*I factors is good; 
between .76 and .95 for the factor ‘discounting’ and between .78 and .93 for the factor ‘lack 
of understanding’. This provides additional support for using Model 3c. 
 
DISCUSSION 
This study investigated the measurement invariance of the 3*I across rheumatic disease, 
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gender, and language version. Our results confirm the validity of a two-factor structure of the 
3*I comprising discounting and lack of understanding for each source (spouse, family, 
medical professionals, work environment, and social services) in patients with rheumatic 
diseases. Strong measurement invariance (i.e., constrained factor loadings and thresholds) 
across rheumatic disease (fibromyalgia versus other rheumatic disease) and across gender was 
established. Strong measurement invariance across the six language versions of the 3*I was 
also supported by adequate fit estimates and by good internal consistency of the factors for 
each language. In most cases, the BIC supported strong measurement invariance, but not all 
estimates showed the best fit for this model. Because most models under investigation had a 
moderate to high RMSEA (.08-.14) and about equal CFI and TLI fit statistics, our model 
selection was largely based on BIC. Although the fit of the model with constrained factor 
loadings and thresholds was not the best across language, measurement invariance of the 3*I 
for languages was not rejected. Because all models (weak, scalar, and strong invariance) 
showed good fit estimates, it is acceptable to conclude that the different language versions of 
the 3*I are comparable.  
This study has some limitations. First, diagnoses were self-reported by patients, and 
there was no certification by a medical specialist. Second, participants were recruited through 
the internet, which may have led to a younger sample from a higher social economic class. 
However, this is less of a problem for the examination of measurement invariance, because 
the instrument should be invariant whether patients do or do not have the disease, are young 
or old, etc. Third, no expert committee was involved in the translation procedure of the 3*I. 
The 3*I is the first instrument to quantify invalidation in patients with rheumatic 
diseases. Results of our study indicate that comparisons between diseases, gender and 
language version of the 3*I are possible, and are likely to be not affected by different 
response styles or different interpretations of items. This is an advantage when examining 
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antecedents and consequences of invalidation as well as the effects of treatments targeting 
invalidation. In clinical practice, the questionnaire can be used to assess invalidation in 
individual patients, which will help therapists to understand and treat patients’ problems.  
 
 
 20 
Acknowledgement We would like to thank all participants for their contribution to this study, 
the patient associations for help in recruiting, and Joop Hox for his expertise and suggestions. 
Funding This study was funded by a grant from the Dutch Arthritis Association 
(Reumafonds). 
Licence for Publication 
The Corresponding Author has the right to grant on behalf of all authors and does grant on 
behalf of all authors, an exclusive licence (or non exclusive for government employees) on a 
worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be 
published in ARD and any other BMJPGL products and sublicences such use and exploit all 
subsidiary rights, as set out in our licence 
(http://group.bmj.com/products/journals/instructions-for-authors/licence-forms). 
Competing Interest: None declared  
Provenance and peer review Not commissioned; externally peer reviewed.  
 
 21 
REFERENCES 
1. Kool MB, Van Middendorp H, Boeije H, et al. Understanding the lack of understanding. 
Invalidation from the perspective of the patient with fibromyalgia. Arthritis Rheum-Arthritis 
Care Res 2009;61:1650-6.  
2. Cunningham MM, Jillings C. Individuals' descriptions of living with fibromyalgia. Clin 
Nurs Res 2006;15:258-73.  
3. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in 
the general population. Arthritis Rheum 1995;38:19-28.  
4. Asbring P, Narvanen AL. Women's experiences of stigma in relation to chronic fatigue 
syndrome and fibromyalgia. Qual Health Res 2002;12:148-60.  
5. Zangi HA, Hauge M, Steen E, et al. "I am not only a disease, I am so much more". Patients 
with rheumatic diseases' experiences of an emotion-focused group intervention. Patient Educ 
Couns 2011;85:419-24.  
6. Kool MB, Van Middendorp H, Lumley MA, et al. Lack of understanding in fibromyalgia 
and rheumatoid arthritis: The Illness Invalidation Inventory (3*I). Ann Rheum Dis 
2010;69:1990-5.  
7. Geenen R. Educating patients and the struggle for validation of fibromyalgia syndrome: 
The Dutch way. J Musculoskelet Pain 2009;17:80-5.  
8. Sass DA. Testing measurement invariance and comparing latent factor means within a 
confirmatory factor analysis framework. J Psychoeduc Assess 2011;29:347-63.  
 22 
9. Mewes R, Christ O, Rief W. Comparing assessment results between cultures. Submitted for 
publication, 2011.  
10. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of 
fibromyalgia. Patient Educ Couns 2008;73:114-20.  
11. Werner A, Malterud K. It is hard work behaving as a credible patient: Encounters between 
women with chronic pain and their doctors. Soc Sci Med 2003;57:1409-19.  
12. World Medical Association (WMA). Declaration of Helsinki. Seoul: WMA; 2008. 
Available from: http://www.wma.net/e/policy/b3.htm. 
13. NetQuestionnaires. Manual NETQ Internet Survey 6.0. Utrecht: NetQuestionnaires 
Nederland BV, 2007. 
14. Dimitrov DM. Testing for factorial invariance in the context of construct validation. Meas 
Eval Counsel Dev 2010;43:121-49.  
15. Reeve BB, Fayers P. Applying item response theory modeling for evaluating 
questionnaire item and scale properties. In: Fayers P, Hays RD, editors. Assessing Quality of 
Life in Clinical Trials: Methods of Practice. 2nd Edition ed. Oxford: Oxford University Press; 
2005: 55-73.  
16. Bowden SC, Weiss LG, Holdnack JA, et al. Equivalence of a measurement model of 
cognitive abilities in US standardization and Australian neuroscience samples. Assessment 
2008;15:132-44.  
 23 
17. Gregorich SE. Do self-report instruments allow meaningful comparisons across diverse 
population groups? Testing measurement invariance using the confirmatory factor analysis 
framework. Med Care 2006;44:S78-94.  
18. Byrne B, Watkins D. The issue of measurement invariance revisited. J Cross Cult Psychol 
2003;34:155-75.  
19. Muthén LK, Muthén BO. Mplus User's Guide, Sixth edition. Los Angeles, CA: Muthén & 
Muthén 2010.  
20. Enders CK, Bandalos DL. The relative performance of full information maximum 
likelihood estimation for missing data in structural equation models. Struct Equ Modeling 
2001;8:430-57.  
21. Van de Schoot R, Lugtig P, Hox J. A checklist for testing measurement invariance. Eur J 
Dev Psychol 2012;9:486-92. 
22. Byrne B, Shavelson R, Muthén B. Testing for the equivalence of factor covariance and 
mean structures - The issue of partial measurement invariance. Psychol Bull 1989;105:456-
66.  
 
 
 24 
Figure 1 Factor structure of the Illness invalidation Inventory (3*I) 
Note. Items of the factor ‘lack of understanding’ have reversed response scores. 
 
